Gene Therapy Genetics Genome Pharma Companies 
pharmaphorum
JANUARY 24, 2023
Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments. Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates.
pharmaphorum
JANUARY 29, 2021
Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
OCTOBER 16, 2023
Dr Salako says there are some clear fields of work associated with different areas, which include: Hertfordshire as a cell and gene therapy hub, with a number of companies in this space clustered around Stevenage. billion in funding.
Drug Discovery World
OCTOBER 4, 2022
This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. billion, compared to $19.9
Pharmaceutical Technology
FEBRUARY 13, 2023
Several biotech companies and researchers are now exploring medical devices and gene therapies to address not just common forms of epilepsy, but also rare conditions such as Dravet Syndrome. New developments in the anti-seizure pipeline Genomic screenings can also be used to sharpen the efficacy of already available treatments.
Drug Discovery World
JANUARY 26, 2023
As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities. According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2% We are seeing the change from traditional biopharmaceuticals to cell and gene therapies.
XTalks
DECEMBER 20, 2023
In 2024, pharma companies and emerging biotechs will improve candidate safety profiles and reduce off-target effects by exploiting predictive intelligence unlocked by AI,” she predicts. CRISPR Gene Editing Therapeutics CRISPR/Cas-9 technology makes lists like this almost every year, and for good reason.
Expert insights. Personalized for you.
96 
Let's personalize your content